Higher doses of CAR-T therapy bring survival advantage for young patients with hard-to-treat B-ALL
COVID-19 lockdown may have increased suicidal thoughts
8 August 2022New injectable gel offers promise for tough-to-treat brain tumors
8 August 2022Higher doses of CAR-T therapy bring survival advantage for young patients with hard-to-treat B-ALL
Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.
